Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.Trump made the announcement at the White House alongside Pfizer CEO Albert Bourla just hours ahead of a possible government shutdown in a partisan standoff over health care and spending.Pfizer Inc., one of the largest U.S. drugmakers, produces the COVID-19 vaccine Comirnaty ...

阿斯利康首席执行官：特朗普政府正在考虑其降低药品价格的提议。 ...

美国总统特朗普：我们将降低药品价格。 ...

Core Viewpoint - The FDA is implementing measures to strengthen state-level import programs to help reduce prescription drug prices [1] Group 1 - The initiative aims to enhance the accessibility of lower-cost medications for consumers [1] - The FDA's actions are part of a broader strategy to address high prescription drug costs in the United States [1] - Strengthening state-level import programs may lead to increased competition and lower prices in the pharmaceutical market [1]

Group 1 - The core viewpoint is that U.S. Health Secretary Kennedy is willing to collaborate with the Democratic Party to create legislation aimed at reducing drug prices [1] Group 2 - The initiative reflects a growing concern over high prescription drug costs in the U.S. healthcare system [1] - The collaboration may lead to significant changes in drug pricing policies, impacting pharmaceutical companies and consumers alike [1]

Core Viewpoint - The article discusses President Trump's signing of an executive order aimed at reducing drug prices in the United States [1] Group 1 - The executive order is part of a broader initiative to lower prescription drug costs for consumers [1] - The order is expected to impact pharmaceutical companies by potentially altering pricing strategies and market dynamics [1] - The administration aims to increase transparency in drug pricing, which may lead to more competitive pricing in the industry [1]